Patients management during hospital stay
Mean duration of hospitalization in an Internal Medicine unit was 11.7 days (range 1–108). The prevalence of atrial fibrillation in the study setting was 18.2%. General characteristics of atrial fibrillation at admission to hospital and specific treatments in patients’ history are listed in Table 2. Of note, in 24% of the patients, atrial fibrillation was first detected during hospitalization. Twelve patients (1.3%) could be classified as having ‘lone’ atrial fibrillation.2
A measure of heart rate at hospital admission and at discharge was available for 740 patients. The percentage of patients with heart rate at rest within the target 60–80 beats/min1 was more than double at discharge (66.3%) vs. hospital admission (30.9%, P < 0.0001). All patients had at least one ECG during hospitalization, and in 40.3% of patients three or more ECGs were recorded. Among the 633 patients with at least two ECGs, 520 had atrial fibrillation at the first exam, and of these 67 had a sinus rhythm at the last control. Holter monitoring was performed in 3.0% of the patients, and echocardiogram in 29.8%. Additional testing related to atrial fibrillation was required in 114 patients (12.6%), and a consultancy by the cardiologist for 96 patients (10.6%).
During hospital stay, 80.5% of the patients received at least one treatment for atrial fibrillation, and the details are provided in Fig. 2. On the whole, 501 patients (55.5%) received an antithrombotic agent for atrial fibrillation, and 558 patients (61.8%) a drug for the arrhythmia which, in the majority of cases (47.2%), was aimed at obtaining rate control (11.2% for rhythm control and 3.4% for both rate with rhythm control). When done, direct current and pharmacological cardioversion were considered effective in four of seven (57.1%) and 38 of 44 (86.4%) patients, respectively.
In the subgroup of patients with diagnosis of atrial fibrillation known before hospitalization, it was shown that during hospital stay rate or rhythm control treatment was introduced in 108 (12.0%) patients, withheld in 58 (6.4%) and maintained in 283 (31.3%). As for antithrombotic prophylaxis, it was introduced in 142 (15.7%), withheld in 113 (12.5%) and maintained in 254 (28.1%) patients.
By combining patients’ history and events that occurred during hospitalization, 116 patients (12.8%) experienced side-effects related to treatment for atrial fibrillation, the more frequent being bleeding (68 patients), bradycardia/other arrhythmias (28 patients) and thyroid dysfunction (six patients).
In-hospital mortality was 13.4%, and 4.6% of the patients were transferred from Internal Medicine to other units. Among the 782 patients discharged from the hospital or transferred to other units, 696 (89%) received prescription of at least one pharmacological treatment for atrial fibrillation (70.2% received a drug for rate or rhythm control and 68.9% an antithrombotic treatment, respectively, Table 3). In addition, 88 patients (11.2%) received prescription for antithrombotic treatment for indication other than atrial fibrillation.
Figure 3 reports the thromboembolic risk profile of patients [according to cardiac failure, hypertension age, diabetes, stroke (CHADS)2 score and indications by the American College of Chest Physicians (ACCP)],12–14 and the percentage of patients receiving antithrombotic treatment for atrial fibrillation at home, in each category. In patients with CHADS2 score of at least 2 or ACCP risk profile ‘intermediate–high’/‘high’, for whom treatment with oral anticoagulant is indicated, antiplatelet agents for atrial fibrillation were prescribed in 28.7 and 28.8% of the patients, respectively. In the case of patients with indications to aspirin or no antithrombotic treatment (CHADS2 score = 0 or ACCP risk profile ‘low’), oral or parenteral anticoagulant was used in 50% of the patients.
Potential predictors for the prescription of oral anticoagulants have been evaluated by means of a multivariable analysis, the results of which are reported in Table 4. Patients with hypertension had a greater chance of being treated with vitamin K antagonists (P < 0.05), although previous bleeding (P < 0.001), age above 75 years (P < 0.001), paroxysmal atrial fibrillation (P < 0.001), male sex (P < 0.01) and a number of concomitant medications of more than four (P < 0.05) were strong negative predictors of prescription of oral anticoagulants.
By reviewing hospital records (SDO), atrial fibrillation was reported at discharge in 682 patients (75.5%). In the details, atrial fibrillation was reported as the primary diagnosis in 31 cases (3.4%), and as the first, second and third or more than third coexisting condition in 22.5, 22.7 and 26.9% of patients, respectively. The more frequent primary diagnoses recorded in SDO were heart failure (28.4%), pneumonia (7.6%), ischaemic stroke (6.3%), respiratory insufficiency (6.0%), cancer (5.5%), acute infection (3.7%) and chronic obstructive pulmonary disease (3.4%).
This observational study provides an updated real-world snapshot of the characteristics and management of patients with atrial fibrillation hospitalized in Internal Medicine wards. Internal Medicine units very often admit patients with advanced age, multiple comorbidities and a number of treatments, and this may considerably influence atrial fibrillation management. In this perspective, our data may be of interest and add interesting information to this topic.
Atrial fibrillation is recognized as an increasingly growing problem of healthcare, owing to a combination of factors including aging, and the rising prevalence of underlying conditions such as ischaemic heart disease or heart failure.1,2,21 Internal Medicine is a setting where this trend may be amplified, owing to the more advanced age and the high number of comorbidities of the patients hospitalized in these units. Our study confirms that atrial fibrillation is a very frequent finding among patients hospitalized in Internal Medicine units, with a prevalence close to 20%. Furthermore, according to our data, around one of 20 patients admitted to Internal Medicine units for any reason receives a diagnosis of ‘de-novo’ atrial fibrillation during the hospital stay.
One of the major findings of our study is the high all-cause in-hospital mortality. In fact, the overall in-hospital death in this study is far higher than that observed in two recent surveys we performed in Internal Medicine units in Italy, the first considering all consecutive patients hospitalized for any cause22 and the second which enrolled patients with heart failure.23 In these two surveys mean age of the patients and burden of comorbidities were slightly lower than those registered in the present study, and this is a plausible explanation for the observed worse prognosis. Although the study design does not allow speculating on this issue, we cannot rule out a possible role of atrial fibrillation per se in determining prognosis, thus confirming that atrial fibrillation is not a benign disease.2 This issue is probably worth addressing in future specifically designed studies.
The present study confirms that patients hospitalized in Internal Medicine units have a high degree of comorbidity, and only very few had ‘lone atrial fibrillation’, with a far lower prevalence if compared with other clinical settings.15,24,25 This condition reasonably affects prognosis, and it influences patient management as well. Of particular interest is the concomitant presence of atrial fibrillation and heart failure which occurred in 29.4% of the patients in our study. It is known that the combination of atrial fibrillation and heart failure is associated with increased morbidity and mortality compared with each disorder alone. Atrial fibrillation and heart failure share common mechanisms and treatment strategies, and drugs such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have been proposed as upstream therapies for atrial fibrillation, both in patients with or without heart failure.1,26
Management of patients with atrial fibrillation involves three principal objectives: rate control, rhythm control and prevention of thromboembolism. Rhythm control was thought to have potential advantages over rate control, but this concept is at present only theoretical, given the findings from large randomized clinical trials which showed that rate control seems safer and as effective as rhythm control.27,28 This suggests that available rhythm control strategies are probably inadequate and that there is an unmet need for safe and efficacious antiarrhythmics for control of atrial fibrillation.15 In this perspective, new drugs such as dronedarone or atrial specific agents could enrich the therapeutic scenario in the near future.11,29 Although some aspects of rate control are still under debate (optimal target of heart rate, lenient vs. strict rate control),1,2,30,31 this strategy is, therefore, preferred by most physicians as therapy for patients with atrial fibrillation. Rhythm control may be considered as an initial approach for younger individuals, especially those with paroxysmal lone atrial fibrillation, and should be applied only in symptomatic patients.2 Coherently with these assumptions, and with the high percentage of permanent atrial fibrillation we observed, in our study the majority of patients received typical rate control drugs (digoxin/β-blockers, verapamil or diltiazem), and drugs for rhythm control were more frequently used in symptomatic than in asymptomatic patients (18 vs. 8.6%) and in those with paroxysmal vs. non-paroxysmal atrial fibrillation (27.6 vs. 11.7%).
Atrial fibrillation is a strong, independent risk factor for stroke.32,33 A number of algorithms are available to stratify the risk of stroke in patients with atrial fibrillation, the most popular being based on the CHADS2 score13,14 and the indications by the American College of Chest Physicians.12 We applied these classifications to the patients of our study, and they appeared to have an elevated risk, as more than three-quarters of the patients were in those categories (CHADS2 score 2–6 /ACCP risk intermediate–high or high) for which guidelines recommend treatment with oral anticoagulants. In our study, the number of patients in the lowest classes of risk was very limited. If related to a recently proposed scoring system, called Cardiac failure, hypertension, age at least 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74 years, sex category (female)34 only six patients in our population (0.6%) belonged to the category which would not need any antithrombotic therapy.
The incidence of stroke in patients with atrial fibrillation can be substantially reduced by using antithrombotic prophylaxis33 and, therefore, an antithrombotic preventive treatment is recommended for the majority of atrial fibrillation patients, including those with paroxysmal atrial fibrillation.1,2,12 However, several observational studies have documented in different settings that compliance with the above recommendation is far from satisfactory, especially with respect to oral anticoagulants.15,20,32,35–37 In our study, the overall mean percentage of patients receiving an antithrombotic treatment for atrial fibrillation was around 55% during hospitalization and near 70% at discharge. This difference can be only partially accounted for by the high rate of patients without antithrombotic therapy who died. The figures of antithrombotic treatment assessed in our study are not easy to compare with data from the literature, due to heterogeneity among available studies as for design and target population. The percentage of antithrombotic treatment we observed at discharge was slightly higher than those previously reported in Italy in in-patients37 and outpatients,20 but lower than those shown in prospective registries in cardiologic settings.15,16 Furthermore, the retrospective design of the study did not allow exact identification of patients with actual contraindication to antithrombotic treatment, and we cannot draw any conclusion on the suboptimal use of antithrombotics. However, if we also consider the background use of antithrombotics for indications other than atrial fibrillation, three of four of our patients received chronic preventive antithrombotic treatment at discharge.
Although there is a consensus that oral anticoagulants offer better protection than antiplatelets against ischaemic stroke in patients with atrial fibrillation,1,2,38–40 these drugs are frequently underused in patients with atrial fibrillation, with reported percentages of prescription between 30 and 60% in most of the studies.15,20,37,41–43 The tendency toward underuse of oral anticoagulants seems confirmed in our study. In fact, at least 75% of the patients had indication for this treatment according to CHADS2 score or ACCP, but less than half actually received it. The gap between guidelines and clinical practice is not completely attributable to the presence of contraindications, although they are not negligible in atrial fibrillation patients.44–46 As known, vitamin K antagonists are cumbersome to use, and the caring doctors have a number of factors to consider in evaluating whether a patient should receive oral anticoagulants or not. In our study, patients with hypertension were more frequently treated with vitamin K antagonists, while previous bleeding, age above 75 years, paroxysmal atrial fibrillation, male sex and a number of concomitant drugs of more than four were strong negative predictors of prescription of oral anticoagulants. Hypertension is a major risk factor for stroke, and its presence led physicians to adopt preventive anticoagulation more frequently. Despite the risk of stroke being similar for paroxysmal vs. persistent/permanent atrial fibrillation,47,48 as previously reported,32 we showed that classification of atrial fibrillation guided the treatment decision toward the use of oral anticoagulant, although it should not be the case. Of interest is the negative association between the number of concurrent medications and treatment with oral anticoagulant, opposite to that shown by a recent survey in the setting of primary care.20 This finding may be due to the concern that polytherapy will increase the risk of bleeding, or that patients with a significant burden of diseases may have more disadvantages than benefits from anticoagulant treatment. The same may apply to the negative correlation between aging and prescription of vitamin K antagonists.
As a further explanation for the gap between indication and prescription of oral anticoagulants, some authors have suggested a lack of awareness among clinicians of patient risk stratification criteria, or poor appreciation of the risk–benefit ratio of vitamin K antagonists, with an overestimation of their bleeding risks.20,49 In our study, risk stratification criteria did not significantly drive the use of oral anticoagulants, as these drugs were prescribed at discharge in 31.5% of the patients with CHADS2 score 0–1 and in 34.1% of those with CHADS2 score 2–6. However, it has to be kept in mind that in clinical practice anticoagulation treatment is highly dependent on the individual patient and takes into account factors such as age, feasibility of adequate monitoring of therapy, comorbidities and the patient's lifestyle and personal preference. Thus, the decision not to give anticoagulants for a patient eligible for anticoagulation may still be the most appropriate strategy for that individual. Apart from this, it is likely that at present anticoagulation in patients with atrial fibrillation is globally suboptimal. Simplification of thromboprophylaxis in atrial fibrillation patients is long overdue for real-life clinical practice, and the availability of the new anticoagulants that would overcome the inherent restrictions and disadvantages of vitamin K antagonists may facilitate their use.50–51
Our study, due to its design, may have some intrinsic limitations. Retrospective audits may be affected by incomplete data recording in the source documents, and we cannot exclude that this has led to underestimation of some figures (e.g. those related to patients’ history, or adverse events due to treatment for atrial fibrillation). Furthermore, some assessments, such as patients’ eligibility for anticoagulant treatment, were difficult to make. On the contrary, the retrospective design of the study allows a rigorous description of the management of patients in clinical practice which was not influenced by the study itself. Our study had a descriptive aim, and it was neither powered to assess prevalence of atrial fibrillation in Internal Medicine units nor the association between anticoagulant treatment and predictors of use. For this latter, we were not able to include in our analysis potential predictors such as those related to social environment, or cognitive status of the patient. The information we provide has, therefore, to be taken as an indication, although reliable and interesting. Finally, our study was confined to two regions of Italy, and we cannot tout court extrapolate the results either to the whole country or to the overall setting of Internal Medicine units. However, as we included hospitals of different location (from cities to small towns) and healthcare organization, we consider our setting representative enough of Internal Medicine units in Italy. It is possible that the therapeutic approach of patients with atrial fibrillation may be different between Internal Medicine and Cardiology wards, owing to reasons such as different age and comorbidities of the patients. A response to this question will be provided by the ATA-AF study (collaborative research ongoing in Italy and involving scientific societies in the cardiology – ANMCO – and the internal medicine –FADOI – field).
In conclusion, atrial fibrillation is a frequent finding in patients hospitalized in Internal Medicine units, with a prevalence of nearly 20%. Patients with atrial fibrillation hospitalized in Internal Medicine units are of advanced age, with a high grade of comorbidity, and characterized by a severe prognosis. These features, added to the existence of some ‘grey zones’ even in the most recent international guidelines (especially in the elderly), make management of patients challenging. More precise indications on some open issues relevant to patients’ treatment and improved treatment strategies (convenient to use other than effective and safe) are needed to optimize atrial fibrillation management in the heterogeneous real-world clinical practice.
The study was supported by an unrestricted grant from Sanofi Aventis Italia, having no involvement in the study design, management, analysis and reporting.
There are no conflicts of interest.
The authors are indebted to Irene Zaratti and Davide Ghilardi for data management and organization.
Members of the FALP Study Group:
F. Orlandini (La Spezia); R. Cavaliere, C. Norbiato (Torino); I. Brandolin, F. Raggi (Genova); M.C. Bertoncelli (Vercelli); A. Rossi (Novara); P. Davio, G. Aiosa, C. Donati (Alessandria); E. Haupt, D. Bessarione (Lavagna - GE); F. Torta, A. Martini (Chieri - TO); M. Delucchi, M.P. Checcucci, S. Reynaud (Saluzzo - CN); C. Marengo, M. Grigoletto (Moncalieri - TO); G. Imperiale (Torino); C. Pascale, A. Bosio, F. Cerrato, O. Pallisco (Torino); S. Pesce, M. Giannotti (Genova); M. Dugnani, G. Cornaglia (Galliate - NO); G. Bertinieri, S. Giovannetti (Biella); T. Defranceschi, R. Durante (Albenga - SV); M. Carosio, A. Marandino (Pinerolo - TO); G. Calò (Verbania).
1. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Circulation
3. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol
4. Feinberg WM, Blackshear JM, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention the AnTicoagulation and Risk Factors in Atrial fibrillation (ATRIA) study. JAMA
6. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J
7. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Monitoba Follow-Up Study. Am J Med
8. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet
9. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke
10. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med
11. Morrow JP, Reiffel JA. Drug therapy for atrial fibrillation: what will its role be in the era of increasing use of catheter ablation? Pacing Clin Electrophysiol
12. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest
13. Gage BF, Waterman AD, Shannon W, Bochler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke results from the National Registry of Atrial Fibrillation. JAMA
14. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation stroke risk stratification in patients taking aspirin. Circulation
15. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J
16. Meiltz A, Zimmermann M, Urban P, Bloch A. on behalf of the Association of Cardiologists of the Canton of GenevaAtrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace
17. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract
18. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA Study. Circulation
19. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart
20. Mazzaglia G, Filippi A, Alacqua M, et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost
21. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure treatment: considerations for a dual epidemic. Circulation
22. Gussoni G, Campanini M, Silingardi M, et al. on behalf of the GEMINI Study GroupIn-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in internal medicine. Thromb Haemost
23. Biagi P, Gussoni G, Iori I, et al.
Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI ‘CONFINE’ study. Int J Cardiol
2011; [Epub ahead of print]
24. Murgatroyd FD, Camm AJ. Atrial arrhythmias. Lancet
25. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace
26. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis inhibition of renin–angiotensin system prevents new-onset atrial fibrillation. Am Heart J
27. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med
28. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med
29. Oyetaio OO, Rogers CE, Hofmann PO. Dronedarone: a new antiarrhythmic agent. Pharmacotherapy
30. Dorian P. Rate control in atrial fibrillation. N Engl J Med
31. Van Gelder IC, Groenveld HF, Crijns HJGM, et al. for the RACE II InvestigatorsLenient versus strict rate control in patients with atrial fibrillation. N Engl J Med
32. Waldo A, Becker RC, Tapson VF, Colgan KY. for the NABOR Steering CommitteeHospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol
33. Hart RG, Pearce LA, Aguilar MI. Meta-analysis antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
34. Apostolakis S, Shantsila E, Lip GY, et al. Contra: ‘antiplatelet therapy is an alternative to oral anticoagulation for atrial fibrillation’. Thromb Haemost
35. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med
36. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ
37. Monte S, Macchia A, Pellegrini F, et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J
38. Connoly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet
39. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet
40. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2
score = 1. Thromb Haemost
41. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation
42. Go AS, Hylek EM, Borowski LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med
43. Goto S, Bhatt DI, Rother J, et al. on behalf of the REACH Registry InvestigatorsPrevalence, clinical profile and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J
44. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet
45. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J
46. Bravata DM, Rosenbeck K, Kancir S, Brass LM. The use of warfarin in veterans with atrial fibrillation. BMC Cardiovasc Disord
47. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. J Am Coll Cardiol
48. Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost
49. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol
50. De Caterina R, Kristensen SD, Renda G. New anticoagulants for atrial fibrillation. J Cardiovasc Med (Hagerstown)
51. Hylek EM. The need for new oral anticoagulants in clinical practice. J Cardiovasc Med (Hagerstown)
Keywords:© 2013 Italian Federation of Cardiology. All rights reserved.
antiarrhythmic drug; atrial fibrillation; Internal Medicine; oral anticoagulants; risk factors